IMPORTANCE Early-life epilepsies are often a consequence of numerous neurodevelopmental disorders, most of which are proving to have genetic origins. The role of genetic testing in the initial evaluation of these epilepsies is not established.
tory and results of clinical examinations, neuroimaging, and metabolic testing, etiology was categorized as acquired brain injuries (ie, hypoxic-ischemic encephalopathy, intraventricular hemorrhage, stroke, trauma, and infections), focal cortical dysplasia, other brain malformations and abnormalities (eg, lissencephaly, polymicrogyria, and septo-optic dysplasia), tuberous sclerosis complex, other neurocutaneous diseases, metabolic diseases, recognizable dysmorphic syndromes (eg, Down syndrome and Wolf-Hirschhorn syndrome), and other disorders (eg, tumors). Microcephaly without specific structural abnormality was considered a brain malformation. When etiology could not be assigned to one of these categories, it was considered "unexplained." The unexplained group was further divided into those with normal developmental status (including mild or equivocal delays) and those with developmental delay based on the clinician's report from the examination and history initially and during the year after diagnosis.
The use and yield of genetic testing in each category for etiology were determined based on results of all testing performed before, at, and during the year immediately following initial epilepsy diagnosis. Genetic testing included tests generating cytogenetic, copy number, or DNA sequencing data. Metabolic testing and clinical examinations, while used in genetic diagnosis, were not considered to be genetic testing for these purposes. All testing was for clinical purposes and based on the discretion of the treating clinician. Variants were reviewed in light of current information by 2 of us (a boardcertified clinical cytogeneticist [M.K.] and a board-certified clinical molecular geneticist [J.J.A.]). When warranted, interpretations were updated. Patterns of use and yield of genetic testing were specifically examined in children with initially unexplained etiology with respect to age at onset, presence of infantile spasms, and developmental delay.
Analyses were performed in SAS, version 9.4 (SAS Institute). Bivariate analyses were performed in PROC SURVEYFREQ 27 and multivariable logistic regression analyses in PROC GLIMMIX 28 to adjust for clustering of observations by center treated as a random variable. Confidence intervals were constructed with standard errors that incorporate clustering of patients by site. P < .05 was the minimal level accepted as reflecting statistical significance.
Key Points
Question What is the diagnostic yield of genetic testing when used for children with newly presenting early-life epilepsy?
Finding In this cohort study of 775 children, diagnostic yields overall were 40%, with epilepsy gene-sequencing panels and whole-exome sequencing having substantially greater diagnostic yields than chromosomal microarray. In the absence of a clinically identified cause, testing yields were greater than 15% and as high as 47% depending on patient subgroups.
Meaning Genetic testing, especially with sequencing-based methods, should be incorporated into the routine initial evaluation of early-life epilepsy.
Results
Twenty families declined participation, and 775 eligible children were recruited (367 girls and 408 boys). The number of children per site varied from 4 to 131 (median, 31). The median age at onset of epilepsy was 7.5 months (interquartile range [IQR], 4.2-16.5 months), and the median age at diagnosis was 8.7 months (IQR, 5.0-19.2 months). Onset occurred at less than 12 months of age in 509 children (65.7%), 12 to 23 months of age in 151 children (19.5%), and 24 to 35 months of age in 115 children (14.8%). Within 1 year of initial presentation with epilepsy, 272 children (35.1%) were diagnosed with infantile spasms (spasms), 63 (8.1%) had other specific electroclinical diagnoses, and 440 (56.8%) had nonsyndromic epilepsy presentations. The electroclinical diagnoses were Dravet syndrome (n = 11); myoclonic epilepsy of infancy (n = 9); myoclonic-atonic (astatic) epilepsy (n = 6); febrile seizures-plus (n = 5); Ohtahara syndrome, benign epilepsy of infancy, benign familial infantile epilepsy, and absence epilepsy (n = 4 each); benign familial neonatal epilepsy, early myoclonic encephalopathy, and epilepsy with myoclonic absence (n = 3 each); malignant migrating focal seizures in infancy and Lennox-Gastaut syndrome (n = 2 each); and myoclonic epilepsy with nonprogressive disorders, benign epilepsy with centrotemporal spikes, and gelastic seizures with hypothalamic hamartoma (n = 1 each). Thirty-four children with initially nonsyndromic presentations evolved to spasms, and 2 with spasms evolved to Lennox-Gastaut syndrome. All 36 are counted only once in the spasms group.
Evaluations and Findings
Neuroimaging Overall, 620 children (80.0%) underwent epilepsy protocol magnetic resonance imaging (MRI) 11 at initial evaluation (n = 534) or within the year following (n = 86). Ninety-four children (12.1%) underwent nonepilepsy protocol MRI, 11 children (1.4%) underwent computed tomographic scans or ultrasonography, and 50 children (6.5%) had no imaging performed during the study. For all 725 neuroimaging studies combined, 273 (37.7%) yielded findings that either provided a specific diagnosis (eg, lissencephaly or tumor) or indicated a developmental or progressive brain disorder. . Sixteen children received a diagnosis of the following metabolic diseases: Leigh syndrome (n = 4), nonketotic hyperglycinemia (n = 3), Zellweger syndrome (n = 2), mitochondrial diseases (n = 2), and 1 child each of methylmalonic acidemia, vitamin B 12 dependency, pyruvate dehydrogenase deficiency, GM 1 gangliosidosis, and Alper-Huttenlocher disease.
Metabolic Testing

Initial Etiology Assignment Before Genetic Testing
Based on history and results of clinical examinations, neuroimaging, and metabolic testing, the initial etiology assignments were acquired brain injuries (n = 95), focal cortical dysplasia (n = 21), other brain malformations and abnormalities (n = 91), tuberous sclerosis complex (n = 20), other neurocutaneous disorders (n = 12), metabolic diseases (n = 16), dysmorphic syndromes (n = 45), other disorders (n = 29), unexplained with developmental delay (n = 122), and unexplained with normal development (n = 324).
Genetic Testing
To target children in whom neurogenetic factors might play an explanatory role, analyses focused on children without documented acquired brain injury (n = 680). Of these children, 327 (48.1%) underwent some genetic testing: 94 before initial epilepsy evaluations, 171 during initial evaluations, and 135 during the following year. Sixty children underwent testing at multiple time points. At the time of initial evaluations, 44 children already had the following laboratory-confirmed genetic diagnoses: trisomy 21 (n = 18), other trisomies and tetrasomies (n = 4), chromosomal deletions or duplications of varying sizes detected by karyotyping or CMA (n = 14), and single-or multiplenucleotide variants identified through sequencing (n = 8). Testing as part of the epilepsy evaluation (through 1 year) identified explanatory pathogenic variants in 88 more children for a total of 132 (40.4%), including 4 with variants of uncertain significance reclassified as pathogenic (Figure 1 ; eTable in the Supplement).
Ten children were carriers for autosomal recessive disorders, which corresponded to their clinical diagnoses in 2 children. The first child had frontally predominant lissencephaly with cerebellar hypoplasia associated with a heterozygous pathogenic RELN (OMIM 600514) mutation (eFigure in the Supplement). The second child was clinically diagnosed with Leigh syndrome and had a heterozygous pathogenic variant of NDUFAF5 (OMIM 612360). Sixty-six other children had variants of uncertain significance in potentially relevant genes. Twenty children had clinical genetic diagnoses that were not confirmed through genetic testing (3 also had a variant of uncertain significance): 7 with Down syndrome, 11 with tuberous sclerosis complex, 1 with neurofibromatosis, and 1 with Kabuki syndrome.
Chromosomal microarray was the most commonly used test (n = 188), followed by a sequencing-based epilepsy gene panel (n = 114), karyotypes (n = 59), WES (n = 33), mitochondrial gene tests (nuclear and mitochondrial; n = 20), and various disease-targeted tests (n = 94; eg, for tuberous sclerosis complex or lissencephaly). The proportion of children tested varied among the 17 sites (median, 49% [IQR, 40%-62%]). When genetic testing was performed, the median pathogenic yield across centers was 40% (IQR, 36%-45%).
Diagnostic (pathogenic) yields from each type of test were meaningfully high. For the 3 broad tests, the yields were as follows: 32 of 188 children for CMA (17.0%; 95% CI, 11%-23%), 31 of 114 children for epilepsy panels (27.2%; 95% CI, 17%-38%), and 11 of 33 children for WES (33.3%; 95% CI, 16%-51%). Variants of unknown significance and heterozygous mutation in autosomal recessive genes were found for all test types (Figure 2) . Of 22 patients with both CMA and WES, 8 of 21 (38.1%) with negative CMA results had diagnostic results of WES, whereas the results of WES were negative and the results of CMA were diagnostic for 1 patient. Similarly, of 44 children with both CMAs and epilepsy panels, 10 of 43 (23.3%) with negative CMA results had diagnostic epilepsy panels. The converse occurred for 1 patient.
Genetic testing was frequently used regardless of initial etiology ( Table 1) . For most categories of etiology, the overall yield exceeded 20%. One notable exception was focal cortical dysplasia, for which all test results (on blood-derived DNA) were negative.
Genetic Testing Yield With Initially Unexplained Etiology
In the group of children with unexplained etiology, 180 of 446 children (40.4%) received some form of genetic testing before (n = 19), as part of (n = 103), and in the year immediately (Figure 3 ). Pathogenic variants were identified before (n = 4 [all developmentally delayed]), during (n = 18), and in the year immediately following (n = 26) initial epilepsy evaluations. Genetic testing was ordered 2 to 3 times as often for infants (<1 year) than for older patients, for those with vs without definite developmental delay, and for those with spasms initially and during the year after initial epilepsy diagnosis ( Table 2) . In a multivariable logistic model, each factor independently contributed to the likelihood of being tested. On bivariate analysis, diagnostic yields did not significantly differ by age at onset or developmental delay but were substantially lower overall for children with spasms and especially when limited to infants. Because spasms are strongly associated with delays and early age at onset, all 3 factors were strongly associated with pathogenic test results in a multivariable model.
Discussion
Our results provide a contemporary assessment of the use of genetic testing in US pediatric epilepsy centers and its diagnostic value for children with newly presenting ELE. Whereas most studies focus on genetic testing in convenience samples of patients selected for severe presentations and outcomes, we targeted all eligible patients at participating centers with ELE at initial diagnostic presentation. After excluding children with acquired brain injuries, the precipitating etiology could be linked to a specific genetic factor in 40% of children, including those with brain malformations, metabolic diseases, or dysmorphic syndromes. Genetic testing provided a diagnosis in one-fourth of children whose cause would have otherwise remained unresolved.
Magnetic resonance imaging is recommended in the evaluation of ELE, Where neonatal metabolic screening for inborn errors of metabolism is not commonly available, this practice is good policy. In our cohort, however, only 1 child had a metabolic condition that typically would be identified at birth (methylmalonic acidemia) but was only found later. Most children with neurometabolic diseases had other signs of metabolic disorders, Although results of genetic testing were negative for children with focal cortical dysplasias, these lesions are often due to somatic mutations that may only be detectable through very deep sequencing of testing of brain tissue-derived DNA. 39, 40 In the future, therapies may be directed toward molecular pathways and may result in a fundamental shift in how etiologies are grouped and classified for clinical purposes. a A total of 4 children who were evaluated prior to the onset of epilepsy and who received genetic diagnoses are excluded. All had seizure onset at 1 year of age or younger and were developmentally delayed. Two had infantile spasms.
b Overall percentage adjusted for site clustering as a random effect.
c Overall percentage after adjustment for other factors. Site is treated as a random effect.
d Noted at initial diagnosis or within the year following initial diagnosis.
e At initial diagnosis or within 1 year of initial diagnosis.
f Multivariable model not adjusted for site due to failure to converge.
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Limitations
Important limitations of this study include that it is not population-based; there may be a selection of patients sent to hospital centers according to severity at initial presentation. Patients were not further selected, however, and they represent newly presenting patients initially diagnosed at these centers. Given that participating hospitals are located across the United States and serve diverse communities, we suspect that our findings are relevant to other centers in this country or elsewhere. They do not, however, reflect non-hospital-based practice. Data come from review of medical records, and pediatric epileptologists at each site ensured the quality of the recorded data elements. Genetic testing reports, however, were not always available for review, especially when testing occurred before epilepsy presentation. In those instances, the variants in the medical record, as reported and used by the treating clinicians, were accepted.
Children did not undergo systematic genetic testing, although all tests were performed at Clinical Laboratory Improvement Amendments-certified facilities. Tests were ordered by physicians at their discretion. Consequently, there were expected trends in the use of genetic testing by key clinical features. Diagnostic yields, however, were meaningfully high regardless of these features, although they were low for spasms. Ideally, all children should receive the same thorough, comprehensive test battery.
Expanding comprehensive genetic testing to all children with ELE could yield many benefits, including stratification of patients in trials of disease-targeted therapies. 41 ); in our study, there were 12 children with SCN1A variants, 2 children with KCNQ2-associated epilepsies, and no children with SCN2A-associated epilepsies. The lack of evidence to guide treatment based on genetic diagnosis occurs because the individual genetic disorders are rare and currently not routinely identified due to an uneven and sometimes unenthusiastic uptake of genetic testing. 45, 46 If testing is not performed and genetic diagnoses are not made, there is no basis for identifying optimal, targeted treatments. Prioritizing thorough, comprehensive genetic testing as part of the initial epilepsy evaluation could make precision medicine part of standard clinical practice. Ideally, the inclusion of genetic testing would result in better health outcomes and reduce costs due to overuse of unnecessary but currently reimbursed diagnostic modalities, 47 including metabolic testing.
48
Aside from treatment selection, multiple benefits accrue to the health system and the family by obtaining a genetic diagnosis. 49 It ends the diagnostic odyssey during which parents and physicians spend untold amounts of time searching for an explanation for a child's epilepsy 50 and reduces associated costs. 47 A genetic diagnosis allows for genetic counseling of parents who may wish to have more children and the consideration of risk for other siblings once they are ready to plan families. 51 A genetic diagnosis creates the opportunity to participate in research studies of new therapies and to find optimal therapy and management approaches for the child or for others in the future. The most successful rare disease network, Children's Oncology Group, 52 has been effective in turning clinical care into research and feeding results back into care, continuously improving survivorship and other outcomes of young patients with cancer. Finally, a genetic diagnosis allows families to seek out others and advocate for research into these rare conditions through a variety of channels, such as the National Organization for Rare Disorders.
53
Conclusions
Growing evidence suggests that early, effective intervention for seizures may modify the severity of developmental, behavioral, and other outcomes for children with ELE. [54] [55] [56] This evidence provides added impetus to move the diagnosis of the specific cause to the point of initial presentation. Our study provides an initial assessment of the potential diagnostic value of such a strategy and suggests that it is time to provide greater emphasis on and support for thorough genetic evaluations, particularly sequencing-based evaluations, for children with newly presenting epilepsies in the first few years of life. 
